Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Sangamo Therapeutics Inc. Stock

Price
Target price
€9.69

€9.69

-1.170%
-0.158
-1.170%
€14.49

€14.49

 
Latest predictions
-
31.07.20
€7.00
25.07.20
-
16.07.20
buy
-
02.06.20
buy
€8.00
29.03.20
buy
€15.00
02.03.20
buy
Your prediction

Sangamo Therapeutics Inc. Stock

A loss of -1.170% shows a downward development for Sangamo Therapeutics Inc..
We see a rather positive sentiment for Sangamo Therapeutics Inc. with 8 Buy predictions and 2 Sell predictions.
With a target price of €14.00 there is a positive potential of 44.494% for Sangamo Therapeutics Inc. compared to the current price of €9.69.

Comments

Buy Sangamo Therapeutics Inc.

Buy Sangamo Bioscienes

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Sangamo Therapeutics Inc. Stock

Trading Sangamo Bioscienes

Trading Sangamo Bioscienes

New thread Forum

News

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize

Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market

Sangamo Announces R&D Organization Changes


Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.



Going forward, research and development will each be managed as separate functions

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy


Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene

Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m

Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20

Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.



“I’m proud of how the Sangamo team has

Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and

Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes

Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of

Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells


Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO)

Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will

Sangamo Announces Closing of Biogen Collaboration Agreement


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:




  • Cowen 40th Annual Health Care

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.



“This quarter marked an

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases


Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before

Sangamo Therapeutics Appoints John Markels to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general